Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03921021 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03921021 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 17 participants.
The verdict
NCT03921021, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.
Interventions
- DRUG Telomelysin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2023-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03921021
The ClinicalTrials.gov registry entry for NCT03921021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telomelysin is the first listed.
NCT03921021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03921021 about?
NCT03921021 is a clinical study titled "Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma". This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.
What is the current status of trial NCT03921021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-05-09. Estimated completion is 2023-07-20.
What interventions are being tested in trial NCT03921021?
The interventions under investigation include: Telomelysin (DRUG).
Who is sponsoring clinical trial NCT03921021?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.